In June 2024, the FDA approved Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity — making it the first GLP-1 medication to receive a specific sleep apnea indication. For the roughly 30 million Americans with obstructive sleep apnea, and especially the large proportion whose OSA is driven by excess weight, this approval opened a new category of treatment options.
But patient questions have outpaced the headline. Many people are searching for information about Ozempic and other GLP-1s for sleep apnea, wondering whether semaglutide produces similar benefits, whether Zepbound replaces CPAP, how strong the evidence actually is, and whether insurance will cover it. This guide answers those questions.
What Is Obstructive Sleep Apnea?
Obstructive sleep apnea (OSA) is a condition in which the upper airway repeatedly collapses during sleep, causing partial or complete breathing interruptions. Each interruption — an apnea or hypopnea event — triggers brief arousal from sleep, preventing deep, restorative rest and reducing blood oxygen levels throughout the night.
OSA severity is measured by the apnea-hypopnea index (AHI): the average number of breathing interruptions per hour of sleep.
- Mild OSA: 5–14 events/hour
- Moderate OSA: 15–29 events/hour
- Severe OSA: ≥30 events/hour
Untreated OSA is associated with serious downstream consequences: hypertension, cardiovascular disease, type 2 diabetes, metabolic syndrome, cognitive impairment, and significantly elevated accident risk from daytime somnolence. CPAP therapy remains the most effective treatment for moderate-to-severe OSA — but adherence is notoriously poor, with many patients discontinuing within months.
Obesity is the strongest modifiable risk factor for OSA. Excess adipose tissue around the neck, jaw, and upper airway physically narrows the passage, increases collapsibility, and reduces upper airway muscle tone. Weight loss has long been recognized as therapeutically effective for OSA — but sustained, meaningful weight loss has historically been extremely difficult to achieve without surgery.
Why GLP-1 Medications Are Clinically Relevant for Sleep Apnea
The logic connecting GLP-1 therapy to sleep apnea benefit is straightforward: GLP-1 medications produce the kind of sustained, substantial weight loss that previously required bariatric surgery.
In the SURMOUNT-1 trial (tirzepatide for obesity), participants lost an average of 22.5% of body weight at the highest dose — a level of weight reduction previously associated primarily with surgical intervention. With weight loss of that magnitude, the structural changes in the upper airway are clinically meaningful.
The key quantitative measure is AHI reduction. In the SURMOUNT-OSA trials (the trials that supported Zepbound's sleep apnea approval), tirzepatide produced median AHI reductions of approximately 25–30 events per hour over 52 weeks. To put that in context: a patient starting with severe OSA (AHI of 45) who achieves that reduction may end treatment with mild OSA (AHI of 15–20) — a clinically significant shift in both sleep quality and cardiovascular risk profile.
Zepbound's FDA Approval: What It Covers
The Zepbound (tirzepatide) approval for OSA, announced in June 2024, is specifically for:
- Adults with moderate-to-severe obstructive sleep apnea (AHI ≥ 15 events/hour)
- Obesity (BMI ≥ 30 kg/m²)
This approval does not extend to mild OSA or to patients who are overweight (BMI 27–29.9) without reaching the obesity threshold. The approval also does not replace the OSA diagnosis requirement — a sleep study (polysomnography or home sleep test) documenting AHI ≥ 15 is required before prescribing for this indication.
The approval was based on two Phase 3 randomized trials (SURMOUNT-OSA Trial 1 and Trial 2). Trial 1 enrolled patients not using CPAP; Trial 2 enrolled patients already using CPAP. Both demonstrated statistically significant and clinically meaningful AHI reductions compared to placebo, along with improvements in sleep-specific symptom scores and several cardiovascular biomarkers.
For a full comparison of Zepbound versus the diabetes-indicated brand (Mounjaro — same molecule, different approval), see our Zepbound vs Mounjaro guide.
What About Ozempic and Semaglutide for Sleep Apnea?
Semaglutide — the active ingredient in Ozempic (diabetes indication) and Wegovy (weight management indication) — does not have an FDA-approved indication for sleep apnea as of 2026. Any use for this purpose is off-label.
This does not mean semaglutide is ineffective for OSA. The mechanistic rationale is identical to tirzepatide: semaglutide produces substantial weight loss (average of ~15% in the STEP trials), which reduces upper airway adipose tissue and improves AHI. Multiple observational studies and case series in the literature have reported AHI improvements in patients with OSA who lost significant weight on semaglutide.
The differences between semaglutide and tirzepatide for sleep apnea are:
- Regulatory status: Tirzepatide has an FDA OSA approval; semaglutide does not
- Magnitude of weight loss: Tirzepatide produces greater average weight loss than semaglutide, which likely translates to greater AHI reduction on average
- Insurance coverage: Tirzepatide has a billing pathway for OSA that semaglutide lacks
- Dedicated trial data: SURMOUNT-OSA trials were specifically designed to measure sleep apnea outcomes; semaglutide's OSA data comes from secondary endpoints and observational analyses
For most patients specifically seeking GLP-1 therapy for sleep apnea, Zepbound is the appropriate first choice when they qualify for the approved indication. Semaglutide may be considered for patients who cannot tolerate tirzepatide, have insurance coverage for Wegovy but not Zepbound, or have other clinical reasons to prefer semaglutide — but this involves off-label use for the OSA indication.
Does GLP-1 Therapy Replace CPAP?
This is among the most common patient questions, and the honest answer is: for most patients with moderate-to-severe OSA, probably not fully — at least not immediately.
CPAP works by delivering positive air pressure that physically holds the airway open throughout the night. It does not depend on weight loss, is effective regardless of the anatomical cause of OSA, and produces AHI normalization in nearly all compliant users within the first night.
GLP-1 therapy works through weight loss, which is gradual. Most patients lose the majority of their weight over 6–18 months, and AHI improvements follow that curve. During the period of active weight loss, patients may still have clinically significant OSA that requires treatment.
The SURMOUNT-OSA trials showed that tirzepatide produced meaningful AHI reductions both with and without concurrent CPAP — which supports the drug's standalone effectiveness. But in clinical practice, many sleep medicine specialists recommend:
- Continuing CPAP while GLP-1 therapy takes effect
- Repeating a sleep study after significant weight loss (typically ≥10% of body weight)
- Reassessing CPAP need based on follow-up AHI results
For patients with mild OSA, or for those who have already achieved substantial weight loss and are near OSA remission thresholds, discontinuing CPAP may become appropriate — but this decision should be guided by objective sleep study results, not symptom improvement alone.
What the AHI Numbers Mean in Practice
Understanding what a 25–30 event/hour AHI reduction means for quality of life is important for setting realistic expectations.
A patient with baseline AHI of 40 (severe OSA) who achieves a 25-point reduction ends treatment with an AHI of approximately 15 — the threshold for mild OSA. This patient may experience dramatically improved sleep quality, lower daytime sleepiness, better cognitive performance, and reduced cardiovascular risk — even if they still technically have some residual sleep-disordered breathing.
The proportion of patients who achieve AHI normalization (below 5 events/hour, the threshold for OSA diagnosis) with tirzepatide is lower than with CPAP — not all patients with severe OSA will reach that level. But the proportion who move from severe to mild or moderate, or from moderate to mild, is substantial — and that shift has real clinical and quality-of-life consequences.
Understanding where you fall on the GLP-1 weight loss curve also matters. Our GLP-1 weight loss timeline guide walks through what to expect month by month, which helps patients understand roughly when OSA improvement is likely to become meaningful.
Insurance Coverage for Zepbound for Sleep Apnea
The FDA approval creates a pathway for insurance coverage that was not available before June 2024. Coverage reality in 2026 is mixed but improving:
Commercial insurance: Some commercial payers cover Zepbound for OSA; many have added it to formularies with prior authorization requirements. The key is using the OSA ICD-10 code (G47.33) alongside the obesity diagnosis in the prior authorization request, rather than the weight management pathway.
Medicare: Medicare Part D traditionally excluded obesity medications. The OSA approval creates a potential coverage angle — Medicare may cover medications for OSA even if the obesity weight management indication is excluded. This is actively being clarified by CMS and varies by plan. Patients should ask specifically whether Zepbound for OSA (not for weight loss) is covered.
Medicaid: Coverage varies by state. The OSA approval has prompted some state Medicaid programs to add coverage pathways, but implementation is not uniform.
Documentation required for most prior authorizations:
- Polysomnography or home sleep test report confirming AHI ≥ 15
- BMI ≥ 30 at time of prescribing
- Provider documentation of sleep apnea as a treatment indication
- Sometimes: documentation of prior CPAP trial
Finding a Provider
Prescribing Zepbound for sleep apnea requires coordination between obesity medicine, sleep medicine, and the patient's primary care provider. The ideal workflow involves:
- Sleep study confirming moderate-to-severe OSA
- BMI ≥ 30 confirmed
- Consultation with a provider experienced in GLP-1 therapy for metabolic and comorbid conditions
- Prior authorization submission using the OSA indication
- Monitoring plan: follow-up sleep study after significant weight loss to reassess AHI and CPAP need
Telehealth providers who focus exclusively on weight management may not be equipped to navigate the sleep apnea indication. Providers with obesity medicine certification or a background in metabolic medicine are more likely to be familiar with the approval and the prior authorization process.
Use the TeleHealthAlly provider comparison tool to find providers who manage complex metabolic conditions and multiple comorbidities — and ask specifically whether they have experience prescribing Zepbound for sleep apnea.
Frequently Asked Questions
Is Ozempic FDA-approved for sleep apnea?
No. Semaglutide (Ozempic, Wegovy) does not have an FDA-approved indication for sleep apnea. Tirzepatide (Zepbound) is the only GLP-1 medication with FDA approval for obstructive sleep apnea, specifically for adults with moderate-to-severe OSA and obesity. If you qualify for the Zepbound OSA indication, that is the appropriate first choice. Use of semaglutide for sleep apnea improvement, while mechanistically reasonable, is off-label.
How do GLP-1 medications improve sleep apnea?
Primarily through weight loss. Excess adipose tissue around the neck and upper airway narrows the passage and increases airway collapsibility. GLP-1 medications produce sustained, substantial weight loss — reducing this tissue, improving airway tone, and lowering apnea-hypopnea index. In SURMOUNT-OSA trials, tirzepatide produced median AHI reductions of approximately 25–30 events per hour. Some researchers also propose direct GLP-1 receptor effects on respiratory control, though the weight-loss mechanism is the primary driver.
Can I use Zepbound for sleep apnea without CPAP?
SURMOUNT-OSA showed meaningful AHI reductions in patients not using CPAP. Zepbound can be effective for OSA as a standalone treatment. However, most sleep medicine specialists still recommend considering CPAP during the period of active weight loss — since GLP-1-driven AHI improvement is gradual. A follow-up sleep study after significant weight loss (typically ≥10% body weight) can guide a decision about discontinuing CPAP.
Will insurance cover Zepbound for sleep apnea?
Coverage is expanding but not universal. Some commercial insurers and Medicare Advantage plans cover Zepbound for OSA with prior authorization. The key is submitting with the sleep apnea ICD-10 code (G47.33) alongside the obesity diagnosis, rather than relying on the weight management pathway alone. Medicaid coverage varies by state. Work with your provider to document the OSA indication clearly in the prior authorization.